Clinical trial · Observational
Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center prospective study involving analysis of circulating tumor DNA (ctDNA) and the gut microbiome in patients with metastatic breast cancer on standard of care endocrine therapy with an aromatase inhibitor in combination with an inhibitor of the cyclin-dependent kinases 4 and 6 (CDK 4/6). Up to 20 patients with Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) metastatic breast cancer and Eastern Cooperative Oncology Group (ECOG) performance status 0-1 will be enrolled. This study involves the collection and analysis of patient samples and does not involve therapeutic intervention.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Time to treatment failure
- timeFrame
- 12 months
- description
- Time from first treatment on study (standard of care aromatase inhibitor and a CDK 4/6 inhibitor) until the date of treatment discontinuation
Secondary outcomes (4)
- measure
- Correlation between specific mutations in ctDNA and in archival tissue samples (where available from prior testing) with time to treatment failure
- timeFrame
- 12 months
- description
- Identification of mutations in archival tissue samples (where available from prior testing) and sequencing of ctDNA using next generation sequencing panel
- measure
- Diversity and composition of the gut microbiome in patients with ER+ HER2- metastatic breast cancer
- timeFrame
- 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Sign written and voluntary informed consent * Histological confirmation of advanced ER positive and HER2 negative breast cancer. * Adult patients at least 18 years of age * ECOG performance status equal to 0 or 1 * Able to provide written informed consent * Must be willing to provide blood for ctDNA analysis on study enrollment and at specified study time points * Must be willing and able to perform stool sample collection * Patients must be suitable, as per their treating physician, for initiation of first line endocrine therapy with an aromatase inhibitor and a CDK 4/6 inhibitor for metastatic disease Exclusion Criteria: * Prior treatment with CDK 4/6 inhibitors in the neoadjuvant or adjuvant setting * Use of targeted therapies other than endocrine therapies alone in the neoadjuvant or adjuvant setting * Relapse on prior endocrine therapy or within 6 months of discontinuation of prior adjuvant endocrine therapy * History of inflammatory bowel disease, chronic diarrhea or malabsorption syndromes and significant prior bowel resection as judged by the study investigator * Use of immunosuppressants including steroids within the previous 4 weeks of planned Cycle 1 Day 1 treatment
References
Publications (0)
Data not yet available